{"analyses":[{"ciLowerLimit":"0.268","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.510","estimateComment":"The hazard ratio was obtained from a stratified Cox model using cGvHD severity at randomization as strata.","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"<0.0001","pValueComment":"The p-value was derived from a 1-sided stratified log-rank test.","paramType":"Hazard Ratio (HR)","paramValue":"0.370","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"The median FFS time was not reached due to an insufficient number of participants with events.","groupId":"OG000","lowerLimit":"18.6","upperLimit":"NA","value":"NA"},{"groupId":"OG001","lowerLimit":"5.6","upperLimit":"6.5","value":"5.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"165"},{"groupId":"OG001","value":"164"}],"units":"Participants"}],"description":"Composite time to event endpoint incorporating the following FFS events: (i) relapse or recurrence of underlying disease or death due to underlying disease, (ii) nonrelapse mortality, or (iii) addition or initiation of another systemic therapy for cGvHD.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ruxolitinib was administered orally twice per day at a dose of 10 milligrams (mg).","id":"OG000","title":"Ruxolitinib"},{"description":"Participants received best available therapies (BATs), including, but not limited to, extracorporeal photopheresis (ECP), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), infliximab, rituximab, pentostatin, imatinib, and ibrutinib based on the investigator's decision.","id":"OG001","title":"Best Available Therapy"}],"paramType":"MEDIAN","populationDescription":"FAS. Data reported are from the start of the study to Cycle 7 Day 1 (data cutoff of 08 May 2020).","reportingStatus":"POSTED","timeFrame":"Baseline to when the last participant reached Cycle 7 Day 1 (each cycle was comprised of 4 weeks)","title":"Rate of Failure-free Survival (FFS)","type":"SECONDARY","unitOfMeasure":"months"}